AndrewCookMD

Breast Cancer, Gynecologic Cancer

Assistant Professor

Dr. Cook is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Andrew Cook is a Radiation Oncologist based in Chicago, IL. He completed his medical education at Rush Medical College, followed by an internship at Loyola University Medical Center, and a residency in Radiation Oncology at Henry Ford Hospital. Dr. Cook has contributed to several publications, including research on prophylactic gabapentin for oral mucositis pain, clinical toxic effects post-lung stereotactic body radiation therapy, and adjuvant management strategies for uterine serous carcinoma. His work has been published in reputable journals and cited by other publications multiple times.

PubMed

In Reply to Smith et al.
Farzan Siddiqui, Andrew Cook
International Journal of Radiation Oncology, Biology, Physics. 2022-08-01
14 citations
Randomized Phase III, Double Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal ...
Andrew Cook, Ankit Modh, Haythem Ali, Jawad Sheqwara, Steven S. Chang
International Journal of Radiation Oncology, Biology, Physics. 2021-11-19
8 citations
An Analysis of Clinical Toxic Effects and Quality of Life as a Function of Radiation Dose and Volume After Lung Stereotactic Body Radiation Therapy
Suneetha Devpura, Aharon M Feldman, Samuel Rusu, Essa Mayyas, Avielle Movsas
Advances in Radiation Oncology. 2021-11-01

Modeling the Power of VaccinesJanuary 9th, 2023
Brain Cancer Therapy Shows Promise in Pediatric Clinical TrialJuly 15th, 2022
$New Antibody Therapy Shows Promising Results for Advanced, Treatment-Refractory Pediatric Brain Cancer$
New Antibody Therapy Shows Promising Results for Advanced, Treatment-Refractory Pediatric Brain CancerJuly 14th, 2022
Join now to see all